As part of our effort to discover new -glucosidase inhibitors from natural sources, it was found that an aqueous extract from Melampodium perfoliatum (Cavanilles) Kunth (Asteraceae) inhibited the activity of rat-intestinal -glucosidases in a concentration dependent manner (IC 50 = 958 g/mL). Fractionation of the active extract led to the isolation of perfoliatin A (1), which was active against the mammal α-glucosidases and a recombinant α-glucosidase with maltase-glucoamylase activity obtained from Ruminococcus obeum. Kinetic analysis revealed that the interaction of 1 with R. obeum-α-glucosidase was noncompetitive. The calculated Ki was 0.68 ± 0.034 mM. In vivo testing using an oral sucrose tolerance test, in healthy and hyperglycemic mice, revealed that perfoliatin A (1) reduced significantly the postprandial peak, consistent with its α-glucosidase inhibitory activity. The effect was comparable or better to that of acarbose, a therapeutically used -glucosidase inhibitor. Altogether, these findings clearly supported the -glucosidase inhibitory activity of melampolide-type of sesquiterpene lactones.
The global prevalence of type II diabetes has risen considerable in the last five years; the International Diabetes Federation estimates that are 425 million people with this disease, which is among the top 10 causes of death worldwide. Hence, new therapies for diabetes are very relevant nowadays. Metformin is the first-line medication for the treatment of type II diabetes mellitus, while the use of other well-established agents varies in different regions [1a] . For example, in areas with large consumption of complex carbohydrates, -glucosidase inhibitors are widely used [1b] . These agents competitively and reversibly inhibit -glucosidase enzymes located in the brush border of the small intestine, delaying the digestion of starch and sucrose and the consequent postprandial blood glucose excursions [1b] . Thus, as part of an effort to discover -glucosidase inhibitor lead compounds from natural sources [1c], we have now investigated an infusion of Melampodium perfoliatum (Cavanilles) Kunth (Asteraceae). This is a native medicinal species used to treat gastrointestinal ailments [1d] . Previous chemical investigation resulted in the isolation of a few diterpenoids, polyacetylenes and several sesquiterpene lactones of the melampolides family with anti-inflammatory properties, including perfoliatin A (1) [1e, 1f] .
To identify the presence of α-glucosidases inhibitors in the plant, the infusion of M. perfoliatum was tested in vitro against rat α-glucosidases. The results revelated that the extract inhibited the enzyme activity in a concentration dependent manner (IC 50 = 985.2 ± 31.07 µg/mL). Fractionation of the active extract via partitioning with CH 2 Cl 2 rendered an organic active fraction (at 985 µg/mL inhibited by 60 % the enzyme activity), which was further fractionated using Sephadex open column chromatography, eluting with CH 3 OH. This process yielded perfoliatin A (1), identified by comparing its spectroscopic data with those previously reported [1f] . Perfoliatin A (1) inhibited the activity of both rat small intestine and Ruminocaccus obeum α-glucosidases (Table 1) being more active against the latter enzyme, which is a structural homologue to human intestinal N-maltase-glucoamylase (2QMJ.pdb, 85% coverage) with a highly conserved catalytic domain [2a] . In both cases the inhibition was dependent on the concentration. Acarbose, a commercially available drug, was used as positive control.
Perfoliatin A (1) in vivo using an oral sucrose tolerance test (OSTT) in healthy and hyperglycemic mice ( Figure 2) ; acarbose was also the positive control. As expected, oral administration of 1 (3.16, 10 and 31.6 mg/kg) significantly reduced blood glucose when compared with a vehicle-treated group, with the effect observed comparable or better to that of acarbose. The good activity observed during the oral sucrose tolerance is consistent with the α-glucosidase inhibitory properties demonstrated in vitro. In summary, perfoliatin A (1) is able to prevent postprandial hyperglycemia. This investigation showed, once more, that melampolides type of sesquiterpene lactones are good inhibitors of -glucosidases [2d, 2e].
Experimental
General: General procedures as previously described [2a] .
Plant material:
The aerial parts of M. perfoliatum were collected on August 2015 in Cuernavaca, Morelos, Mexico. A voucher specimen (1468949) was deposited at the National Herbarium (MEXU), Universidad Nacional Autónoma de México, Mexico City.
Extraction and isolation: 250 g of dried of plant material were extracted with 6 L of boiling water during 20 min; filtration and concentration in vacuo yielded 1.5 g of dried extract. Partition of the infusion with CH 2 Cl 2 (3 × 700 mL) yielded 0.8 g of the organic fraction. The CH 2 Cl 2 soluble fraction (800 mg) was subjected to column chromatography on Sephadex LH-20 column (CH 3 OH, 500 ml) to remove pigments. This procedure afforded 60 mg of compound 1, characterized as perfoliatin A [1f].
α-Glucosidase inhibition:
The small intestine rat enzyme was purchased from Sigma-Aldrich (St. Louis, MO); R. obeum enzyme was obtained as previously described [2a] . The experiments and enzyme solutions preparation were performed according a standard procedure [2a] . Acarbose (positive control) was dissolved in phosphate buffer solution (PBS, 100 mM, pH = 7) and compound 1 was dissolved in CH 3 OH. The concentration required to inhibit activity of the enzyme by 50% (IC 50 ) and the kinetic analysis were conducted following a protocol previously reported [2c] . The mode of inhibition was determined by the Lineweaver-Burk plots [2c] .
In vivo studies: ICR male mice, age 3-4 weeks (25-30 g body weight), were obtained from Envigo Mexico RMS. The animals were maintained under standard laboratory conditions (12 h lightdark cycle and controlled temperature 22 ± 1 °C) and given standard pellet diet and water ad libitum until the beginning of each experiment. All procedures with animals were conducted in agreement with the Mexican Official Norm NOM-062- ZOO-1999 
Nicotinamide-streptozotocin (NA-STZ) induced hyperglycemia:
The experimental hyperglycemia in mice was achieved by giving a single intraperitoneal (i.p.) administration of NA (50 mg/kg). Thirty minutes later, STZ (130 mg/kg) was administrated i.p. to all animals. One week later, mice having blood glucose  200 mg/dL were considered hyperglycemic and selected for the study [2a] .
Collection of blood samples and determination of blood glucose levels: Blood samples were collected from caudal vein, and glucose levels (mg/dL) were determined by the enzymatic glucose oxidase method. The percentage variation of blood glucose levels was calculated as previously reported [2a, 2e] .
Oral sucrose tolerant test: Compound 1 (3.16-31.6 mg/kg) was tested in healthy and NA-STZ-treated mice following the methodology previously reported by our research group [2a, 2e] . Acarbose was the positive control.
Statistical analysis:
Results are expressed as the mean ± standard error. Two-way ANOVA was used to analyze statistical significance differences; followed by Bonferroni's test (p < 0.05).
